Skip to main content
Donald Kohn, MD, Pediatrics, Los Angeles, CA

DonaldBarryKohnMD

Pediatrics Los Angeles, CA

Professor, Pediatrics, UCLA School of Medicine

Dr. Kohn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kohn's full profile

Already have an account?

  • Office

    4650 W Sunset Blvd
    MS 62
    Los Angeles, CA 90027
    Phone+1 323-669-4559
    Fax+1 323-660-1904

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1986 - 1988
  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsResidency, Pediatrics, 1982 - 1985
  • University of Wisconsin School of Medicine & Public Health
    University of Wisconsin School of Medicine & Public HealthClass of 1982

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1987 - 2025
  • WI State Medical License
    WI State Medical License 1983 - 2017
  • American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • T Cell Dynamics and Response of the Microbiota After Gene Therapy to Treat X-linked Severe Combined Immunodeficiency  
    Luigi D Notarangelo, Judith Kelsen, Ronald G Collman, Donald B Kohn, BioMed Central
  • IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System  
    Kenneth Cornetta, Antoni Ribas, Gay M Crooks, Donald B Kohn, Clinical Cancer Research

Lectures

  • Friday Scientific Workshop on Novel Curative Options: Gene-Editing and Gene Therapy for Hemoglobinopathies with a Focus on Sickle Cell Disease 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Completing the Genome Editing Arc in Hematology 
    60th American Society of Hematology Annual Meeting - 12/4/2018

Press Mentions

  • ASH: Gene Therapy for Rare Genetic Disorder, Molecular Insights into Leukemia Growth and More
    ASH: Gene Therapy for Rare Genetic Disorder, Molecular Insights into Leukemia Growth and MoreDecember 2nd, 2024
  • 'A Real Regulatory Dilemma Here': What We Heard This Week
    'A Real Regulatory Dilemma Here': What We Heard This WeekNovember 24th, 2024
  • Novel Gene Therapy Trial for Sickle Cell Disease Launches
    Novel Gene Therapy Trial for Sickle Cell Disease LaunchesNovember 22nd, 2024
  • Join now to see all

Grant Support

  • Transduction Of Hematopoietic Stem Cells For Enhanced Immunotherapy Of MelanomaNational Cancer Institute2010–2012
  • Training In Developmental HematologyNational Heart, Lung, And Blood Institute2011
  • In Vivo ADA Gene Delivery For The Treatment Of SCIDNational Institute Of Allergy And Infectious Diseases2009–2011
  • Gene Therapy Using Hematopoietic Stem CellsNational Heart, Lung, And Blood Institute2009–2011
  • In Vivo ADA Gene Delivery For The Treatment Of SCIDNational Center For Research Resources2009–2011
  • Mnd-Ada Transduced CD34 Cells For Ada-ScidFood And Drug Administration2005–2011
  • Clinical Trial: Transduction Of CD34+ Cells From The Umbilical Cord Blood Of InfNational Center For Research Resources2009
  • Clinical Trial: Long-Term Follow-Up For Studies Of Gene Transfer (Hiv And OthersNational Center For Research Resources2009
  • Lentiviral Vector For Gene Transfer To Hematopoietic Stem CellsNational Center For Research Resources2007–2009
  • In Vivo ADA Gene Delivery For The Treatment Of SCIDNational Institute Of Allergy And Infectious Diseases2007–2008
  • Long-Term Follow-Up For Studies Of Gene Transfer (Hiv And Others)National Center For Research Resources2007–2008
  • Conference--American Society Of Gene TherapyNational Heart, Lung, And Blood Institute2004–2008
  • Transduction Of CD34+ Cells From The Umbilical Cord Blood Of Infants Or The BNational Center For Research Resources2006–2007
  • Gene Therapy For Ada-Deficient SCIDNational Heart, Lung, And Blood Institute2004–2007
  • Gene Therapy Using Hematopoietic Stem CellsNational Heart, Lung, And Blood Institute2003–2007
  • Clinical Trial Planning Grant: Lentiviral Vector For HIV-1National Institute Of Allergy And Infectious Diseases2006
  • Long-Term Follow-Up For Studies Of Gene TransferNational Center For Research Resources2005–2006
  • Lentiviral Vector Transfer To Hematopoietic Stem CellsNational Center For Research Resources2003–2006
  • Treatment Of Severe Combined Immune Deficiency Disease Due To ADA DeficiencyNational Center For Research Resources2005
  • Mnd-Ada Transduced CD34 Cells For Ada-ScidFood And Drug Administration2005
  • Lentiviral Vector Transfer To Hematopoietic Stem CellsNational Institute Of Allergy And Infectious Diseases2002–2005
  • Core A-- Administrative CoreNational Heart, Lung, And Blood Institute2004
  • Treatment Of Severe Combined Immune Deficiency DiseaseNational Center For Research Resources2004
  • Transfer Of Revm10 And FX Genes Into Bone MarrowNational Center For Research Resources2004
  • Transduction Of CD34+ Cells From The Bone Marrow Of HIV-1 Infected ChildrenNational Center For Research Resources1998–2004
  • Gene Expression In Beta-Cells By Lentiviral VectorsNational Institute Of Diabetes And Digestive And Kidney Diseases2002–2003
  • Core--Gene Transduction And Gene TherapyNational Heart, Lung, And Blood Institute2000–2002
  • Retrovirus And Lentivirus For Stem Cell TransductionNational Institute Of Allergy And Infectious Diseases1999–2002
  • In Vitro And In Vivo Models Of Human ErythropoiesisNational Heart, Lung, And Blood Institute1998–2002
  • Transduction Of CD34 Peripheral Blood Progenital Cell From HIV Infected PersonsNational Center For Research Resources1998–2002
  • Mechanisms Of Gene SilencingNational Cancer Institute1996–2002
  • Core--Vector DevelopmentNational Cancer Institute1996–2002
  • Gene Therapy For Hurlers DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2001
  • Hematopoietic Stem Cells For Gene Therapy With REV M10National Institute Of Allergy And Infectious Diseases1998–2001
  • Modified Retroviral Vectors For HSC Gene TherapyNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2000
  • Treatment Of Severe Combined Immunodeficiency Disease Due To ADA DeficiencyNational Center For Research Resources1997–1999
  • In Vivo Model For Human Stem CellsNational Heart, Lung, And Blood Institute1996–1999
  • Core--Gene Therapy/Molecular Biology LaboratoryNational Heart, Lung, And Blood Institute1996–1999
  • Retroviral Transfer Of CDNA For Glucocerebrosidase Into Stem CellsNational Center For Research Resources1996–1999
  • Retroviral Transduction Of Anti-Hiv Ribozyme Into Hematopoietic Stem CellsNational Institute Of Allergy And Infectious Diseases1996–1998
  • Hematopoietic Gene Transfer--Pediatric AIDSNational Institute Of Allergy And Infectious Diseases1996–1997
  • Modified Retroviral Vectors For Stable Gene ExpressionNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1996
  • In Vivo Model Of Human Stem Cell Gene TherapyNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1995
  • Glucocerebrosidase Gene Expression--Hematopoietic CellsNational Institute Of Diabetes And Digestive And Kidney Diseases1994
  • Glucocerebrosidase Gene Expression-Hematopoietic CellsNational Institute Of Diabetes And Digestive And Kidney Diseases1991–1993
  • Retroviral Vector-Mediated Transfer Of Nef GeneNational Institute Of Allergy And Infectious Diseases1989–1991